The alliance brings together Cellular Origins, a company focusing on applying robotics and other forms of automation to CGT ...

The positive results are a major leap forward for Takeda's orexin programme, which looked in jeopardy in 2021 when lead asset ...

The Oligonucleotides for CNS Summit returns for its 5 th year to address key challenges in durability, scalability, potency ...

The readout is particularly welcome for AZ as baxdrostat (formerly CIN-107) showed mixed results in earlier hypertension ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

It is not certain that the new Wearable Behaviour Model (WBM) AI will make it into a finished product – not least because of ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

Also cited in the complaint (PDF) are FDA Commissioner Marty Makary, NIH Director Jay Bhattacharya, who appeared alongside ...

The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

Returning for its second year, the Autoimmunity & Inflammation Partnering & Investment Summit unites over 80 on-scope and ...

So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...

The FDA has called a plan to publish certain complete response letters (CRLs) for medicines it has rejected after an initial ...